Development of Riluzole Analogs with Improved Use-Dependent Inhibition of Skeletal Muscle Sodium Channels
- PMID: 37465302
- PMCID: PMC10350938
- DOI: 10.1021/acsmedchemlett.3c00224
Development of Riluzole Analogs with Improved Use-Dependent Inhibition of Skeletal Muscle Sodium Channels
Abstract
Several commercially available and newly synthesized riluzole analogs were evaluated in vitro as voltage-gated skeletal muscle sodium-channel blockers. Data obtained from the patch-clamp technique demonstrated that potency is well correlated with lipophilicity and the introduction of a protonatable amino function in the benzothiazole 2-position enhances the use-dependent behavior. The most interesting compound, the 2-piperazine analog of riluzole (14), although slightly less potent than the parent compound in the patch-clamp assay as well as in an in vitro model of myotonia, showed greater use-dependent Nav1.4 blocking activity. Docking studies allowed the identification of the key interactions that 14 makes with the amino acids of the local anesthetic binding site within the pore of the channel. The reported results pave the way for the identification of novel compounds useful in the treatment of cell excitability disorders.
© 2023 American Chemical Society.
Conflict of interest statement
The authors declare no competing financial interest.
Figures
References
-
- Hays S. J.; Rice M.; Ortwine D. F.; Johnson G.; Schwarz R. D.; Boyd D. K.; Copeland L. F.; Vartanian M. G.; Boxer P. A. Substituted 2-benzothiazolamines as sodium flux inhibitors: quantitative structure-activity relationships and anticonvulsant activity. J. Pharm. Sci. 1994, 83 (10), 1425–1432. 10.1002/jps.2600831013. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Chemical Information
